WALTHAM, Mass., June 06, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (Nasdaq:BGNE), a clinical-stage biopharmaceutical company focused on developing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that it will present at the Goldman Sachs 37th Annual Global Healthcare Conference in Rancho Palos Verdes, California. The presentation is scheduled for 9:20 a.m. PT on Thursday, June 9, 2016.
A live webcast can be accessed from the investors section of BeiGene’s website at http://ir.beigene.com/. An archived replay will be available for 90 days following the event.
About BeiGene
BeiGene is a global, clinical-stage, research-based biotechnology company focused on molecularly targeted and immuno-oncology cancer therapeutics. With a team of over 215 scientists, clinicians and staff in China, the United States, Australia and Taiwan, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is working to create combination solutions aimed to have both a meaningful and a lasting impact on cancer patients.
Media/Investor Contact:
Lucy Li, Ph.D.
+1 781-801-1800
ir@beigene.com
media@beigene.com
Source:
BeiGene, LTD.
